IDEXX Laboratories (IDXX) Q3 2026 earnings review
IDEXX pet test sales speed up, but deal costs trim its profit plan
IDEXX Laboratories, the maker of veterinary diagnostic machines and tests, accelerated its recurring pet sales while a software purchase trimmed its full-year margin plan. Underlying sales grew 10%, led by an 11% gain in recurring pet diagnostics as clinics installed over 1,900 inVue Dx analyzers. Chief executive Mike Erickson raised the full-year sales and earnings outlook for a third straight quarter, though by our math the plan leaves fourth-quarter earnings growth slowing to about 7%.
| Sales from businesses owned a year ago | +10.0% 9.0% last quarter |
|---|---|
| Pet diagnostics recurring underlying sales | +11.0% above ~8.3%–10.7% implied H2 plan |
| Profit per share, excluding one-offs and FX | $3.96 +22% from a year ago |
| Full-year revenue outlook | Raised $32M operating margin outlook cut 0.2 points |
⚖️ Verdict: 🟢 Bullish
The story got better because clinics are using more cartridge and lab tests per machine, pushing recurring pet growth above what the company's own second-half plan pointed to. The caution: buying AI software maker CoVet pushed administrative costs up 16% and forced a 0.2-point cut to the full-year operating margin forecast, while beating the implied third-quarter sales target mainly shows that the prior plan was cautious.
The question now is whether double-digit recurring growth comes from a multi-year jump in test usage from new cancer and needle-sample tests, or mostly from roughly 4% price hikes and a first-year machine placement wave. Because the press release left out US clinic visit traffic and exact price figures, the earnings call and fourth-quarter recurring sales will tell.
🐂 Bull Case
New Analyzers Lifted Pet Recurring Sales
"Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently," chief executive Mike Erickson said. InVue Dx is the veterinary diagnostics maker's slide-free clinic analyzer, and FNA is its test for checking lumps using a needle sample.
Clinics installed more than 1,900 inVue Dx machines during the third quarter, lifting the active base to nearly 11,000 units and putting the 5,500 full-year goal within easy reach. Equipment revenue stayed flat because the company was comparing against last year's initial launch wave, but the bigger machine base drove cartridge and test sales higher.
- Pet diagnostics recurring underlying sales: up 11.0% from a year ago
- VetLab clinic consumables underlying sales: up 14.6% from a year ago
- Global premium instrument installed base: up 11% from a year ago
- InVue Dx placements in the first nine months: about 4,600 units by our math
This matters because IDEXX makes most of its profit on the recurring test supplies that clinics buy after a machine is on the counter. Consumables grew 3.6 percentage points faster than the premium machine base, showing that new tests and higher prices are lifting revenue per clinic.
What to watch: fourth-quarter inVue Dx placements and whether the FNA needle-sample test reaches broad availability by year-end. Broad availability would lift test usage per machine into next year.
International and Reference Labs Held Double-Digit Growth
IDEXX runs two main recurring pet businesses: cartridges for machines inside veterinary clinics, and outside reference laboratories where vets send blood and tissue samples. Both grew at a double-digit pace in the third quarter, helped by overseas clinics and the expansion of IDEXX Cancer Dx, its blood test for canine cancer, into a multi-cancer panel.
Reference laboratory sales from businesses owned a year ago rose 10.2%, matching the second quarter's 10.3% pace on higher testing volume, new clinics and higher prices. Overseas recurring pet diagnostic underlying sales rose 13.6%, outpacing the 9.6% gain in the United States as the Maine-based group expanded its international sales force.
What to watch: reference laboratory underlying growth in the fourth quarter. Holding a 10% pace would confirm that the broader cancer panel is winning clinic accounts from rival labs.
Third Straight Outlook Raise Shows Earlier Caution
Three months ago, IDEXX set a full-year plan for recurring pet diagnostic underlying sales that, by our math, pointed to about 9.5% growth in the second half. Third-quarter underlying sales in that division grew 11.0% instead, beating the top of the implied range.
The pet-care group raised its full-year underlying growth outlook for the division by 0.8 percentage points at the middle of the range, to 10.3%–11.0%. Beating the implied target shows that the earlier plan was cautious, not that US vet clinic traffic has rebounded. By our math, the new full-year target still leaves fourth-quarter underlying recurring growth at 10.2%.
What to watch: fourth-quarter recurring pet diagnostic underlying growth against that 10.2% implied rate. Another beat would show management kept a cushion into year-end.
🐻 Bear Case
CoVet Acquisition Cut the Full-Year Margin Plan
Erickson highlighted the purchase of CoVet, "an AI clinical assistant that supports veterinary team productivity and diagnostics utilization", as a win for customers and shareholders. Cash flow statements show IDEXX spent $227 million on acquisitions over the first nine months, up from $13 million in the first half, and CoVet will add $5 million to 2026 revenue.
The deal came with a near-term profit cost. General and administrative overhead jumped 16.4% from a year ago, rising 0.6 percentage points to 10.2% of revenue, "while absorbing acquisition impacts, including transaction-related costs". Although a 1.1-point drop in the cost of making products lifted third-quarter operating margin to 33.1%, IDEXX cut its full-year operating margin outlook by 0.2 points to 32.1%–32.3%.
What to watch: fourth-quarter operating margin, which the full-year plan puts at 28.8% by our math, down from 28.9% a year ago. A deeper drop would show CoVet's operating losses are heavier than simple deal fees.
Rapid Assay Volumes Keep Falling
Rapid assay products are single-use clinic test kits, such as SNAP tests for tick-borne diseases and heartworm. Underlying revenue in this line rose 0.7% from a year ago to $89.1 million, trailing every other diagnostic line as clinics shifted pancreatic tests onto automated Catalyst machines.
IDEXX said the 0.7% gain came from higher prices, "offsetting lower testing volumes". Relying on price increases to cover shrinking unit sales leaves the $350 million product line vulnerable if veterinary clinics push back on annual price hikes.
What to watch: fourth-quarter rapid assay underlying growth after the Catalyst test shift finishes lapping. Continued volume drops would point to clinics cutting back on routine wellness screening.
Risks this quarter didn't answer
Four standing concerns could not be checked because the figures live in the earnings call, website snapshot or quarterly filing rather than the press release.
- US clinic visit traffic: the release notes that US practice metrics are on the company's website, leaving the third-quarter visit decline and wellness visit trend unreadable here.
- Price contribution: management cited net price gains across divisions but did not state whether price stayed near the roughly 4% pace from earlier quarters.
- Customer credit reserves: accounts receivable rose 8.6% from a year ago and days sales outstanding ticked up 0.2 days to 46.7, while the bad-debt allowance awaits the 10-Q filing.
- Cancer test competition: the release gave no clinic count or rival conversion share for the expanded Cancer Dx panel.
👓 Other Themes
Currency Swung Back to a Full-Year Tailwind
Foreign exchange rates reduced third-quarter revenue growth by 0.2 percentage points, but currency hedges and tax effects still added $0.04 per share to profit. For the full year, IDEXX now expects currency to add about 0.7 points to revenue growth and $0.25 per share to earnings, reversing the prior quarter's forecast of a 0.6-point revenue drag and $0.22 per share headwind.
💲 Other KPIs
Free cash flow — cash from operations after capital spending — rose 13.4% from a year ago, reaching 34.7% of revenue. IDEXX spent $85.6 million on property and equipment over the first nine months and cut its full-year capital spending plan by $20 million to $160 million, lifting its full-year cash conversion forecast.
Buybacks slowed by two-thirds from the second quarter's $332.0 million as the veterinary group used cash to pay for CoVet. IDEXX bought 199,000 shares at an average price of $563.04, down from $570.72 in the second quarter, reducing diluted share count by 2.0% from a year ago to 79.0 million.
Combined sales outside pet healthcare grew 6.1% from a year ago by our math, slower than the second quarter's 13.6% gain. Water testing revenue rose 7.8% on an underlying basis to $58.8 million with a 50.3% operating margin, while livestock, poultry and dairy testing grew 3.0% on an underlying basis to $34.8 million.
🔮 Guidance
Raised. The middle of the range moved up $32 million, including $5 million from CoVet, to 10.1%–10.8% reported growth and 9.3%–10.0% underlying growth. By our math, that leaves fourth-quarter reported growth at 8.4% and underlying growth at 8.6%, down from 10.0% in Q3 as last year's analyzer launch wave is lapped. Third raise this year: +$41.5M, +$5M, +$31.5M.
Raised. Management lifted the underlying growth range by 0.8 percentage points at the middle to 10.65%. By our math, the updated plan leaves fourth-quarter underlying growth at 10.2%, compared with 11.0% in the third quarter and 10.5% in last year's fourth quarter. It is the third raise in three quarters.
Cut. The full-year margin target came down 0.2 percentage points, trimming expected margin expansion to 0.5–0.7 points both as reported and excluding one-offs and currency. By our math, after a 33.3% margin over the first nine months, the outlook leaves fourth-quarter operating margin at 28.8% as CoVet costs weigh on profit.
Raised. The middle of the range rose $0.25 per share, calling for 14%–16% reported growth and 15%–16% growth excluding currency and one-offs. By our math, that leaves fourth-quarter earnings at $3.31 per share, up 7.5% from a year ago against 17.9% growth in Q3. Third raise this year: +$0.13, +$0.14, +$0.25.
Raised. IDEXX lifted the bottom of its cash conversion range by 5 percentage points after trimming planned capital spending by $20 million. Operating cash flow remains guided at 110%–120% of net income. By our math, spending $160 million for the year still requires $74.4 million of capital spending in the fourth quarter, more than double Q3's $28.9 million.
Raised. Lower expected interest expense (down $3 million) and a 0.6-point lower effective tax rate support the higher earnings outlook, while share-based compensation tax benefits stay at ~$19 million ($0.24 per share). The diluted share reduction target tightened to the top end of the prior 1.5%–2% range.
❓ Key Questions
What did US clinic visits do in the third quarter?
The press release directed readers to the website snapshot for US companion animal practice metrics. Because US same-store clinical visits fell 1.3% in the second quarter and were projected down 1.5% in the second half, the Q3 reading is needed to judge underlying demand.
How much will CoVet cost to run in 2027?
IDEXX paid roughly $214 million in the third quarter for CoVet, which adds $5 million to 2026 sales while trimming the full-year operating margin target by 0.2 percentage points. Investors need to know how much of that drag is one-time deal fees versus ongoing operating losses.
What role will the new MultiCue Dx analyzer play?
The company announced it will showcase its next point-of-care analyzer, IDEXX MultiCue Dx, at an Orlando veterinary conference on January 18, 2027. Management has not yet explained what tests the machine runs or whether it replaces an existing clinic analyzer.
Did price increases stay near 4% in the third quarter?
Management credited net price gains in consumables, reference labs and rapid assays, where higher prices masked falling test volumes. Without the exact price percentage, it is impossible to separate true test volume growth from price hikes.